ライフサイエンスコーパス: interleukin-23

1 going chronic inflammation and production of interleukin 23.

2 nt and correlated with reduced production of interleukin 23.

3 he receptor for the proinflammatory cytokine interleukin-23.

4 representative scaffolds and panned against interleukin-23.

5 hemokine genes, including the p19 subunit of interleukin-23.

6 ed levels of tumor necrosis factor alpha and interleukin-23.

7 discovery of the biological functions of the interleukin-23/-17 axis led to the identification of IL-

8 Interleukin-23, a recently described cytokine produced b

9 ependent on inflammatory DCs, which produced interleukin-23 and increased fatty acid oxidation.

10 b, an antibody that binds the p40 subunit of interleukin-23 and interleukin-12 and thereby blocks the

11 Inhibition of interleukin-23 and interleukin-17 may have a role in the

12 expressed high levels of interleukin-1beta, interleukin-23 and interleukin-6, and promoted T-helper

13 cts of lipopolysaccharide on interleukin-12, interleukin-23, and matrix metalloproteinase-9, suggesti

14 on involving high-mobility group protein B1, interleukin-23, and the Th17 pathway.

15 t dominates the binding affinity for an anti-interleukin-23 (anti-IL-23) antibody by using the comple

16 Interleukin-12 and interleukin-23 are inflammatory cytokines implicated in

17 c agents, ustekinumab (an interleukin-12 and interleukin-23 blocker) and etanercept (an inhibitor of

18 ptor-induced secretion of interleukin-12 and interleukin-23 by DCs in an autocrine manner, promoted d

19 nized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit

20 Tumor necrosis factor-alpha, interleukin 23, chemokine C-C ligands 3 and 4, and decti

21 eous candidiasis, probably owing to impaired interleukin 23-dependent interleukin 17 immunity.

22 the activity of these cytokines, inhibiting interleukin-23-dependent production of interleukin-17.

23 Cytokines interleukin-12 and interleukin-23 have been implicated in the pathogenesis

24 To determine whether blockade of the interleukin 23-helper T cell 17 (IL-23-TH17) pathway wit

25 Interleukin 23 (IL-23) and IL-17 have been linked to the

26 atus lung infection in the presence of lower interleukin 23 (IL-23) and IL-17A production in the lung

27 cteria requires the sequential generation of interleukin 23 (IL-23) and IL-22 to induce protective mu

28 Ltbr(-/-) mice lacked interleukin 23 (IL-23) and IL-22, which can regulate SFB

29 Interleukin 23 (IL-23) is integral to the pathogenesis o

30 Interleukin 23 (IL-23) is required for autoimmune inflam

31 Levels of interleukin 23 (IL-23) produced by PBMC from HIV-1-infec

32 ytokine interleukin 12p70 and an increase in interleukin 23 (IL-23) production by gp120-treated mDCs.

33 Here, we observed increased interleukin 23 (IL-23) protein levels in human colon bio

34 egies to examine the effect that blockade of interleukin 23 (IL-23) signaling had on GVH and GVL reac

35 Signaling of interleukin 23 (IL-23) via the IL-23 receptor (IL-23R) a

36 Interleukin 23 (IL-23) was essential for the accelerated

37 Expression of interleukin 23 (IL-23), IL-1 receptor I (IL-1RI), IL-17R

38 17 helper T cell (TH17)-associated cytokine interleukin 23 (IL-23), which was associated with positi

39 r 'imprinted' signaling via the receptor for interleukin 23 (IL-23R) in responding T cells to promote

40 Interleukin-23 (IL-23) and IL-17 are cytokines currently

41 ed to chronic inflammation, particularly via interleukin-23 (IL-23) and IL-17 signaling pathways.

42 Interleukin-23 (IL-23) and the recently discovered Th17

43 Serum concentrations of interleukin-23 (IL-23) are elevated and polymorphisms in

44 tion of LMP7 by PR-957 blocked production of interleukin-23 (IL-23) by activated monocytes and interf

45 this study, we have identified secretion of interleukin-23 (IL-23) by donor antigen-presenting cells

46 In particular, miR-29 downregulated interleukin-23 (IL-23) by targeting IL-12p40 directly an

47 We sought to investigate the role of interleukin-23 (IL-23) deficiency, a cytokine important

48 Interleukin-23 (IL-23) is a heterodimeric cytokine that

49 Interleukin-23 (IL-23) is a pro-inflammatory cytokine re

50 Interleukin-23 (IL-23) is an important proinflammatory c

51 Interleukin-23 (IL-23) is considered a critical regulato

52 Interleukin-23 (IL-23) is one of the key cytokines that

53 Experimental models have shown that interleukin-23 (IL-23) orchestrates innate and T cell-de

54 Here we report that interleukin-23 (IL-23) production by the thymic dendriti

55 accumulated, phagocytosis was impaired, and interleukin-23 (IL-23) production was reduced in Muc5b(-

56 ed by LPS/HI have elevated expression of the interleukin-23 (IL-23) receptor, a marker of early TH17

57 Interleukin-23 (IL-23), a member of the IL-12 family, is

58 Interleukin-23 (IL-23), an IL-12 family cytokine, plays

59 ion of effector CD4(+) T cells stimulated by interleukin-23 (IL-23), but whether these cells are requ

60 We report here that interleukin-23 (IL-23), the cytokine most clearly tied t

61 Maintenance of the Th17 phenotype requires interleukin-23 (IL-23), whereas the Th1-promoting cytoki

62 In interleukin-23 (IL-23)-dependent colitis, there is exces

63 for eosinophils as crucial effectors of the interleukin-23 (IL-23)-granulocyte macrophage colony-sti

64 responses, partly through the production of interleukin-23 (IL-23).

65 d the influence of morphine treatment on the interleukin-23 (IL-23)/IL-17 axis and related innate imm

66 Immunity to OPC is strongly dependent on the interleukin-23 (IL-23)/IL-17R axis, as mice and humans w

67 Human interleukin 12 and interleukin 23 (IL12/23) influence susceptibility or res

68 Levels of interleukin 23 (IL23) and T-helper (Th) 17 cell pathway

69 onoclonal antibody that selectively inhibits interleukin 23 (IL23), a cytokine implicated in the path

70 define a role for TLR-mediated production of interleukin-23 in immune cell homing and pathogenesis.

71 clonal antibody targeting the p19 subunit of interleukin-23, in patients with moderately-to-severely

72 This action of GM-CSF is mediated by its interleukin-23-inducing activity rather than its role as

73 ling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients with moderate-to-s

74 n 6, interleukin 10, IL-17A, interleukin 22, interleukin 23, interferon gamma, kynurenine, and trypto

75 s initiates a cytokine cascade that includes interleukin-23, interleukin-17, and ultimately granulocy

76 D patients did not produce excess amounts of interleukin-23, interleukin-17, or tumor necrosis factor

77 We had previously found a dominant interleukin-23-interleukin-17 signature at inflamed site

78 The discovery of CD4+ Th17 T cells and the interleukin-23/interleukin-17 axis has challenged existi

79 olded protein response and activation of the interleukin-23/interleukin-17 axis have been observed in

80 Activation of the interleukin-23/interleukin-17 axis in spondyloarthritis

81 cells and emerging data suggesting that the interleukin-23/interleukin-17 axis may be involved in th

82 -genome association studies suggest that the interleukin-23/interleukin-17 axis plays an important ro

83 beta and interleukin-6 are critical, whereas interleukin-23 is more important at later stages promoti

84 Interleukin-23 is thought to be critical to the pathogen

85 noclonal antibody against interleukin-12 and interleukin-23, is unknown.

86 we compared guselkumab (CNTO 1959), an anti-interleukin-23 monoclonal antibody, with adalimumab in p

87 ty, humanised, IgG1 kappa antibody targeting interleukin 23 p19 that represents an evolving treatment

88 sted clinical improvement with inhibition of interleukin 23 p19.

89 nflammatory cytokine production, depended on interleukin-23 p19 secretion, whereas interleukin-12 p35

90 eron-gamma as well as interleukin-12 p40 and interleukin-23 p40 secretion.

91 nes that encode factors that function in the interleukin-23 pathway have been associated with a numbe

92 The interleukin-23 pathway is implicated genetically and bio

93 otably, genes whose products function in the interleukin-23 pathway, and transcription factors, inclu

94 this pathway inhibits Th17 cells by limiting interleukin 23 production.

95 NF), major histocompatibility complex (MHC), interleukin 23 receptor (IL23R) and protein tyrosine pho

96 as well as murine models have shown that the interleukin 23 receptor (IL23R) pathway plays a pivotal

97 cleotide polymorphisms (SNPs) mapping to the interleukin-23 receptor (IL-23R) and IL-12beta genes wit

98 ous European studies suggest NOD2/CARD15 and interleukin-23 receptor (IL-23R) donor or recipient vari

99 IL-23 (interleukin 23) regulates immune responses against patho

100 targeting the p19 subunit and thus prevents interleukin-23 signaling, and ustekinumab, an interleuki

101 ed as a major source of IL-22 in response to interleukin 23 stimulation.

102 In humans, interleukin-23 synergizes with interleukin-6 and interle

103 ophagy (eg, ATG16L1, IRGM), and genes in the interleukin-23-T helper cell 17 pathway indicate the imp

104 of pivotal mucosal cytokines, including the interleukin-23/T helper 17 cytokine, interleukin-22.

105 pathways, the most prominent of which is the interleukin-23/Th17 axis.

106 e is known about the effect of specific anti-interleukin-23 therapy, as compared with established ant

107 psoriasis can be achieved with specific anti-interleukin-23 therapy.

108 Therefore, selective blockade of interleukin-23 via inhibition of p19 might be a viable t

109 ody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous inductio

110 tion (MCP1, tumor necrosis factor-alpha, and interleukin-23) were significantly attenuated, whereas a

111 anism involves GM-CSF-mediated production of interleukin-23, which increases apoptosis susceptibility

112 In this phase 2 trial, selective blockade of interleukin-23 with risankizumab was associated with cli